Regenera Pharma

Company Overview

Snapshot

Founded in June 2008, Regenera Pharma operates with 1–10 employees. The company has secured $24.02 million across four funding rounds. In August 2018, Regenera Pharma enrolled its first patient in a US Phase 3 study for RPh201 in NAION and advanced its Phase 2 study in Alzheimer's disease in Canada.

Business overview

Regenera Pharma is a clinical-stage pharmaceutical company focused on developing innovative drugs for the treatment of optic nerve neuropathies, with a particular emphasis on ischemic optic neuropathy. The company's core product, RPh201, is being evaluated in clinical trials for conditions such as NAION and Alzheimer's disease. Regenera operates within the Health Tech & Life Sciences sector, specifically targeting the pharmaceutical and biotechnology industries with its regenerative medicine approach.

Strategic signal

In November 2020, a trustee was appointed for Regenera Pharma, indicating a significant operational challenge or restructuring event for the company. This development signals a critical juncture in the company's trajectory, potentially impacting its ongoing clinical programs and future viability.

Company Intelligence Q&A

What is Regenera Pharma's primary focus?

Regenera Pharma is a clinical-stage pharmaceutical company developing innovative drugs for the treatment of optic nerve neuropathies, with a current focus on ischemic optic neuropathy.

What is the status of Regenera Pharma's operations?

Regenera Pharma ceased to operate in November 2020, at which point a trustee was appointed for the company.

What was a significant clinical milestone for Regenera Pharma in 2018?

In August 2018, Regenera Pharma enrolled its first patient in a US Phase 3 study of RPh201 for NAION and also advanced its Phase 2 study of RPh201 for Alzheimer's disease in Canada.

What was the total capital raised by Regenera Pharma?

Regenera Pharma raised a total of $24.02 million across four funding rounds.